Current Pain and Headache Reports

, Volume 11, Issue 5, pp 339–342 | Cite as

Melatonin therapy in fibromyalgia

  • Russel J. Reiter
  • Dario Acuna-Castroviejo
  • Dun-xian Tan
Article

Abstract

Fibromyalgia (FM) is a painful syndrome that is more common in women than in men. Whether FM has an organic basis or whether it is psychosomatic is debated. Of the numerous treatments that have been tried, rarely have any been completely effective in relieving the pain of FM. Preliminary evidence indicates that melatonin, a molecule that is endogenously produced and is available as an over-the-counter supplement, may be effective in treating the pain associated with this syndrome. Although melatonin is commonly known as a sleep aid (sleep/wake problems are common in FM sufferers), it has a variety of other beneficial effects that may account for its potential benefits in the treatment of FM.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Wolfe F, Ross K, Anderson J, et al.: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995, 38:19–38.PubMedCrossRefGoogle Scholar
  2. 2.
    Wolfe F and the Vancouver Fibromyalgia Consensus Group: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160–172.CrossRefGoogle Scholar
  3. 3.
    Staud R, Robinson ME, Price DD: Isometric exercise has opposite effects on central pain mechanisms in fibromyalgia patients compared to normal controls. Pain 2005, 118:176–184.PubMedCrossRefGoogle Scholar
  4. 4.
    Klein R, Berg PA: A comparative study on antibodies to nucleoli and 5-hydroxytryptamine in patients with fibromyalgia syndrome and tryptophan-induced eosinophilia myalgia syndrome. Clin Investig 1994, 72:541–549.PubMedCrossRefGoogle Scholar
  5. 5.
    Russell IJ, Vaeroy H, Javors M, Nyberg F: Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992, 35:550–556.PubMedCrossRefGoogle Scholar
  6. 6.
    Russell IJ, Michalek JE, Vipraio GA, et al.: Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol 1989, 19:158–163.Google Scholar
  7. 7.
    Vaeroy H, Helle R, Forre O, et al.: Elevated CSF levels of substance P and high incidence of Raynaud’s phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988, 32:21–26.PubMedCrossRefGoogle Scholar
  8. 8.
    Bennett RM, Clark SR, Campbell SM, Burkhardt CS: Low levels of somatomedin C in patients with fibromyalgia syndrome: a possible line between sleep and muscle pain. Arthritis Rheum 1992, 35:1113–1116.PubMedCrossRefGoogle Scholar
  9. 9.
    Geener R, Jacobs JWG, Bijlsma JWJ: Evaluation of endocrine dysfunction in fibromyalgia. Rheum Dis Clin North Am 2002, 38:389–404.CrossRefGoogle Scholar
  10. 10.
    Reiter RJ: The mammalian pineal gland: structure and function. Am J Anat 1981, 162:267–313.CrossRefGoogle Scholar
  11. 11.
    Melyan Z, Tattelin EE, Billingham L, et al.: Addition of human melanopsin renders mammalian cells photoresponsive. Nature 2005, 433:741–745.PubMedCrossRefGoogle Scholar
  12. 12.
    Panda S, Nayak SK, Campo B, et al.: Illumination of melanopsin’s signaling pathway. Science 2005, 307:600–604.PubMedCrossRefGoogle Scholar
  13. 13.
    Moore RY, Speh JC, Card JP: The retinohypathalamic tract originates from a distinct subset of retinal ganglion cells. J Comp Neurol 1995, 352:351–366.PubMedCrossRefGoogle Scholar
  14. 14.
    Reiter RJ: Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocrine Rev 1991, 12:151–180.CrossRefGoogle Scholar
  15. 15.
    Reiter RJ: Melatonin: the chemical expression of darkness. Mol Cell Endocrinol 1991, 79:C153–C158.PubMedCrossRefGoogle Scholar
  16. 16.
    Wikner J, Hirsch U, Wetterberg L, Röjdmark S: Fibromyalgia—a syndrome associated with decreased nocturnal melatonin secretion. Clin Endocrinol 1998, 49:179–183.CrossRefGoogle Scholar
  17. 17.
    Press J, Phillip M, Neumann L, et al.: Normal melatonin levels in patients with fibromyalgia syndrome. J Rheumatol 1998, 25:551–555.PubMedGoogle Scholar
  18. 18.
    Korszun A, Sackett-Lundeen L, Papadopoulos E, et al.: Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol 1999, 26:2675–2680.PubMedGoogle Scholar
  19. 19.
    Klerman EB, Goldenberg DL, Brown EN, et al.: Circadian rhythms of women with fibromyalgia. J Clin Endocrinol Metab 2001, 86:1034–1039.PubMedCrossRefGoogle Scholar
  20. 20.
    Citera G, Arias MA, Maldonado Cocco JA, et al.: The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol 2000, 19:9–13.PubMedCrossRefGoogle Scholar
  21. 21.
    Acuna-Castroviejo D, Escames G, Reiter RJ: Melatonin therapy in fibromyalgia. J Pineal Res 2006, 40:98–99.PubMedCrossRefGoogle Scholar
  22. 22.
    Mease P: Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 2005, 75(Suppl 32):6–21.Google Scholar
  23. 23.
    Lack LC, Wright HR: Clinical management of delayed sleep phase disorder. Behav Sleep Med 2007, 5:57–76.PubMedCrossRefGoogle Scholar
  24. 24.
    Altundag O, Celik H: Total antioxidant capacity and severity of the pain in patients with fibromyalgia. Redox Rep 2006, 11:131–135.CrossRefGoogle Scholar
  25. 25.
    Tan DX, Manchester LC, Terron MP, et al.: One molecule, many derivatives: a never ending interaction of melatonin with reactive oxygen and nitrogen species. J Pineal Res 2007, 42:28–42.PubMedCrossRefGoogle Scholar
  26. 26.
    Larson AA, Giovengo SC, Russell IJ, Michalek JE: Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000, 87:201–211.PubMedCrossRefGoogle Scholar
  27. 27.
    Leon J, Escames G, Rodriguez MI, et al.: Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin. J Neurochem 2006, 98:2023–2033.PubMedCrossRefGoogle Scholar
  28. 28.
    Srinivasan V, Smith M, Spence W, et al.: Melatonin in mood disorders. World J Biol Psychiatry 2006, 7:138–151.PubMedCrossRefGoogle Scholar
  29. 29.
    Zapancic M, Guilleminault C: Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006, 20:981–992.CrossRefGoogle Scholar
  30. 30.
    Terneus W: Pregabalin and duloxetine for the treatment of neuropathic pain disorders. J Pain Palliat Care Phamacother 2007, 21:79–84.CrossRefGoogle Scholar
  31. 31.
    Stewart LS, Leung LS: Hippocampal melatonin receptors modulate seizure threshold. Epilepsia 2005, 46:473–480.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Russel J. Reiter
    • 1
  • Dario Acuna-Castroviejo
  • Dun-xian Tan
  1. 1.Department of Cellular and Structural BiologyUniversity of Texas Health Science CenterSan AntonioUSA

Personalised recommendations